Cost-effectiveness acceptability curve. At a 2019 US WTP of $195 300, SOC is favored over SOC plus caplacizumab in 100% of 10 000 iterations. The ICER range at which caplacizumab is favored in 0.03% to 100% of iterations is USD $1 037 405 to $2 142 668. capla, caplacizumab.